545 related articles for article (PubMed ID: 16622122)
1. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
Thompson IM; Ankerst DP; Chi C; Goodman PJ; Tangen CM; Lucia MS; Feng Z; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Apr; 98(8):529-34. PubMed ID: 16622122
[TBL] [Abstract][Full Text] [Related]
2. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
3. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ; Thompson IM
Urology; 2014 Jun; 83(6):1362-7. PubMed ID: 24862395
[TBL] [Abstract][Full Text] [Related]
5. African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.
Yanke BV; Carver BS; Bianco FJ; Simoneaux WJ; Venable DD; Powell IJ; Eastham JA
BJU Int; 2006 Oct; 98(4):783-7. PubMed ID: 16978273
[TBL] [Abstract][Full Text] [Related]
6. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Vickers AJ; Till C; Tangen CM; Lilja H; Thompson IM
J Natl Cancer Inst; 2011 Mar; 103(6):462-9. PubMed ID: 21350221
[TBL] [Abstract][Full Text] [Related]
7. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
8. Low AUA symptom score independently predicts positive prostate needle biopsy: results from a racially diverse series of 411 patients.
Porter CR; Kim J
Urology; 2004 Jan; 63(1):90-4. PubMed ID: 14751356
[TBL] [Abstract][Full Text] [Related]
9. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
Lucia MS; Epstein JI; Goodman PJ; Darke AK; Reuter VE; Civantos F; Tangen CM; Parnes HL; Lippman SM; La Rosa FG; Kattan MW; Crawford ED; Ford LG; Coltman CA; Thompson IM
J Natl Cancer Inst; 2007 Sep; 99(18):1375-83. PubMed ID: 17848673
[TBL] [Abstract][Full Text] [Related]
10. Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in black American men.
Woods VD; Montgomery SB; Herring RP; Gardner RW; Stokols D
J Natl Med Assoc; 2006 Apr; 98(4):492-504. PubMed ID: 16623061
[TBL] [Abstract][Full Text] [Related]
11. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
12. Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):143-6. PubMed ID: 17269618
[TBL] [Abstract][Full Text] [Related]
13. The digital rectal examination (DRE) remains important - outcomes from a contemporary cohort of men undergoing an initial 12-18 core prostate needle biopsy.
Palmerola R; Smith P; Elliot V; Reese CT; Mahon FB; Harpster LE; Icitovic N; Raman JD
Can J Urol; 2012 Dec; 19(6):6542-7. PubMed ID: 23228289
[TBL] [Abstract][Full Text] [Related]
14. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
Ngo TC; Turnbull BB; Lavori PW; Presti JC
J Urol; 2011 Feb; 185(2):483-7. PubMed ID: 21167519
[TBL] [Abstract][Full Text] [Related]
15. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
16. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black american men but not in white men: results from a consecutive series of 914 men.
Latchamsetty KC; Kim J; Porter CR
J Urol; 2006 Mar; 175(3 Pt 1):913-7; discussion 917. PubMed ID: 16469578
[TBL] [Abstract][Full Text] [Related]
18. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
19. [Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].
Zhu XD; Zheng A; Wang ZQ; Shao Q
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):142-146. PubMed ID: 30156074
[TBL] [Abstract][Full Text] [Related]
20. Stratification of prostate-specific antigen level and results of transrectal ultrasonography and digital rectal examination as predictors of positive prostate biopsy.
Clark TW; Goldenberg L; Cooperberg PL; Wong AD; Singer J
Can Assoc Radiol J; 1997 Aug; 48(4):252-8. PubMed ID: 9282157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
